Acer Therapeutics to Participate in Needham Virtual Healthcare Conference
Get Alerts ACER Hot Sheet
Join SI Premium – FREE
NEWTON, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will present and host one-on-one investor meetings at the upcoming 20th Annual Needham Virtual Healthcare Conference April 12-15, 2021.
| Conference: | 20th Annual Needham Virtual Healthcare Conference | |
| Format: | Virtual presentation and one-on-one meetings | |
| Presentation: | April 15, 2021 | |
| Time: | 11 a.m. Eastern Time | |
| Webcast: | https://acertx.com/investor-relations/events-presentations/ |
About Acer Therapeutics Inc.Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms (iVMS); and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the U.S. FDA. On March 19, 2021, Acer entered into a Collaboration and License Agreement with Relief Therapeutics for worldwide development and commercialization of ACER-001. For more information, visit www.acertx.com.
Investor Contact:Hans VitzthumLifeSci AdvisorsPh: 617-430-7578[email protected]
Jim DeNikeAcer Therapeutics Inc.Ph: 844-902-6100[email protected]
Source: Acer Therapeutics Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mavro Asset Ecosystem Announces August 17 Launch of Public Token Sale on PinkSale
- Best Kid-Friendly Resorts (2026): Westgate Resorts Named Top Family Destination for All-Ages Fun by Expert Consumers
- New Crypto Coins Worth Watching, Led by a Presale That Sold Out Its First Rung
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Needham & Company, Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share